InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 124,000 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
InnoCare Pharma Stock Performance
INCPF stock remained flat at $1.55 during trading on Friday. The stock’s 50 day moving average is $1.55 and its 200 day moving average is $1.58. InnoCare Pharma has a 52 week low of $1.55 and a 52 week high of $2.31.
Wall Street Analysts Forecast Growth
Separately, Morgan Stanley upgraded shares of InnoCare Pharma to an “overweight” rating in a research report on Thursday, May 28th. One analyst has rated the stock with a Buy rating, According to MarketBeat, InnoCare Pharma presently has an average rating of “Buy”.
InnoCare Pharma Company Profile
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Stories
- Five stocks we like better than InnoCare Pharma
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
